20.500.12556/RUL-143424 Adverse effects of levodopa/carbidopa intrajejunal gel treatment a single-center long-term follow-up study Objectives: Levodopa/carbidopa intrajejunal gel (LCIG) is an effective therapeutic strategy to overcome levodopa-induced motor complications in advanced Parkinson's disease (PD). However, it requires invasive percutaneous endoscopic gastrojejunostomy (PEG-J) and may be associated with serious adverse effects (AE). In this study, we aimed to evaluate long-term AEs related to LCIG treatment in a large homogenous cohort of advanced PD patients. Methods: One hundred three consecutive PD patients were regularly monitored for LCIG-related, PEG-J-related, and device-related AEs up to 14 years. Incidence of AEs was studied in time applying a time-to-event analysis and Cox proportional hazard model with age, disease duration, gender, and recurrent AE as covariates. Health-related quality of life (HRQoL) was estimated at each visit and compared to HRQoL before the LCIG treatment. Results: Among 296 AEs noted, 48.8% were LCIG-related, 32.4% PEG-J-related, and 19.6% device-related. While most of the studied AEs steadily accumulated throughout the follow-up period, 24.3% of the patients (95% CI 10.1%–36.3%) experienced PEG-J-related AE already within the first days after the PEG-J insertion. Cox model revealed that older patients had higher probability of psychosis, PEG-J- and device-related AEs (p < .05, p < .05, and p = .02) and suggested increased recurrence risk in those with early PEG-J and device-related AEs. Despite relatively high incidence of AEs, HRQoL significantly increased in the follow-up period (p < .0001). Conclusion: AEs related to LCIG treatment are common. Therefore, careful patient selection and monitoring throughout the treatment is recommended, especially in those with early side effects. Nevertheless, LCIG significantly improves HRQoL in advanced PD patients on a long term. advanced Parkinson's disease levodopa-carbidopa intestinal gel percutaneous endoscopic gastrojejunostomy adverse effects health-related quality of life nevrologija napredovala Parkinsonova bolezen levdopa-karbidopa gel perkutana endoskopska gastrojujenostoma kvaliteta življenja stranski učinki true false true Angleški jezik Slovenski jezik Članek v reviji 2022-12-20 13:08:49 2022-12-20 13:08:50 2022-12-21 03:36:53 0000-00-00 00:00:00 2022 0 0 Str. 537-544 iss. 5 Vol. 146 2022 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.8 0001-6314 10.1111/ane.13675 117250307 Acta_Neuro_Scandinavica_-_2022_-_Rus_-_Adverse_effects_of_levodopa_carbidop.pdf Acta_Neuro_Scandinavica_-_2022_-_Rus_-_Adverse_effects_of_levodopa_carbidop.pdf 1 806F73C7318EB67E571CF76972019DE6 4ad6d40368ec71598b6d86c717a708fc8b3077f63247e98785cfe1352070b93a 5459b7ad-805f-11ed-9c94-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=165114 https://onlinelibrary.wiley.com/doi/10.1111/ane.13675 0 47bf6bbc-805f-11ed-9c94-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=165112 Medicinska fakulteta 0 0 0